Table 1.

Patient characteristics at the entry of the trial.

Subject no	Age	Racial/ethnicity	Local therapy	Prior treatment	No of cycles	Best response
001	83	Caucasian	Prostatectomy	1998: prostatectomy; 2000: Salvage radiation; since 2004: intermittent ADT; 2015: enzalutamide	1	Unable to determine *Patient received only one cycle with rising PSA
002	66	Hispanic	Definitive radiation	2009: XRT; since 2011: intermittent ADT; 12/2015–09/2016, bicalutamide	42 cycles, ongoing	CR
003	74	Caucasian	Neoadjuvant docetaxel + ADT followed by prostatectomy	2013: neoadjuvant docetaxel + ADT; 2013: RALP; 2014: ADT; 01/15–08/19: bicalutamide	14	PR
004	79	Native American	Prostatectomy	2007: radical prostatectomy; 2013: ADT; 09/2014–04/2016: apalutamide; 07/2016–09/2016: docetaxel	6	SD
005	76	African American	Prostatectomy	2008: prostatectomy; 02/2013: ADT; 03/16–09/19: bicalutamide	32 cycles, ongoing	CR
006	86	Caucasian	None	2015: ADT + bicalutamide	6	PR
007	73	Caucasian	Definitive radiation plus ADT	2015: XRT plus ADT; 1/17: ADT and Deoctaxel, with disease progression; 04/17: cabazitaxel;	2	PD# Possibly neuroendocrine cancer with visceral mets and high chromogranin
008	78	Caucasian	XRT + 6 mo ADT	1998: XRT + 6 mo ADT; 02/2016: ADT; 04/17: Sipeulucel T	3	PD
009	79	Caucasian	None	04/2016: ADT + bicalutamide	18, ongoing	PR

CR complete response, PR partial response, SD stable disease, PD progression of disease.

*Patient received only one cycle of treatment at the trial with rising PSA but without clinical progression and was taken off from the trial. Per PCWG2 criteria, if PSA is the only sign of disease progression, patient should be treated for up to 12 weeks.

^#This patient might have neuroendocrine tumor as he had widespread visceral metastasis and high serum chromogranin.